Lexeo Therapeutics (LXEO) Invested Capital (2022 - 2026)

Lexeo Therapeutics has disclosed Invested Capital across 5 years of filings, most recently posting $231.5 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $231.5 million, up 162.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $231.5 million (up 162.72% YoY), and the FY2025 annual result was $246.7 million, up 111.11% from the prior year.
• Invested Capital came in at $231.5 million for Q1 2026 at Lexeo Therapeutics, down from $246.7 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $246.7 million in Q4 2025 to a low of -$162.8 million in Q3 2023.
• The 5-year median for Invested Capital is $116.8 million (2024), against an average of $59.6 million.
• Across the five-year window, Invested Capital sank 64.49% in 2023 and soared 239.46% in 2024, its largest moves.
• Lexeo Therapeutics' Invested Capital stood at -$113.0 million in 2022, then soared by 200.51% to $113.5 million in 2023, then climbed by 2.91% to $116.8 million in 2024, then jumped by 111.11% to $246.7 million in 2025, then retreated by 6.15% to $231.5 million in 2026.
• The last three Invested Capital figures came in at $231.5 million (Q1 2026), $246.7 million (Q4 2025), and $120.8 million (Q3 2025), per Business Quant data.